<!DOCTYPE html>
<html lang="tr">
<head>
<link rel="icon" type="image/png" sizes="32x32" href="/favicon.png"><link rel="icon" type="image/png" sizes="16x16" href="/favicon-16.png">
<script src="/scripts/https-redirect.js"></script>
<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
<script>
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());
 gtag('config', 'G-QBM7E0EHFP');
</script>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>GLP-1 mi, ESG mi? 9 Boyutta KapsamlÄ± KarÅŸÄ±laÅŸtÄ±rma | UzunYaÅŸa</title>
    <meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
 <meta name="description" content="Ä°laÃ§ tedavisi mi, endoskopik prosedÃ¼r mÃ¼? Etkinlik, kalÄ±cÄ±lÄ±k, maliyet ve daha fazlasÄ± â€” doÄŸru karar iÃ§in 9 kritik boyut.">
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&family=Playfair+Display:wght@500;600&display=swap" rel="stylesheet">
 <link rel="stylesheet" href="../../styles/main.css">
 <link rel="stylesheet" href="../../styles/animations.css">
 <style>
 article { max-width: 800px; margin: 0 auto; padding: 7rem 2rem 4rem; }
 .post-meta-top { display: flex; gap: 1rem; flex-wrap: wrap; margin-bottom: 1.5rem; }
 .post-category { display: inline-block; background: #6366f1; color: white; padding: 0.4rem 1rem; border-radius: 20px; font-size: 0.8rem; font-weight: 600; }
 .reading-time { color: var(--text-gray); font-size: 0.9rem; }
 h1 { font-family: 'Playfair Display', serif; font-size: 2.3rem; font-weight: 600; line-height: 1.2; margin-bottom: 1rem; }
 .subtitle { font-size: 1.15rem; color: var(--text-gray); margin-bottom: 2rem; }
 .featured-image { width: 100%; height: 280px; background: linear-gradient(135deg, rgba(99,102,241,0.7), rgba(79,70,229,0.7)), url("https://images.unsplash.com/photo-1576091160399-112ba8d25d1d?w=800&q=80") center/cover; border-radius: 16px; margin-bottom: 2rem; display: flex; align-items: center; justify-content: center; }
 .featured-image span { font-size: 4rem; }
 .content p { margin-bottom: 1.5rem; font-size: 1.05rem; }
 .content h2 { font-size: 1.5rem; font-weight: 700; margin: 2.5rem 0 1rem; color: var(--primary); padding-top: 1rem; border-top: 1px solid #e5e7eb; }
 .content h3 { font-size: 1.2rem; font-weight: 600; margin: 1.5rem 0 0.75rem; }
 .content ul { margin: 1.5rem 0; padding-left: 1.5rem; }
 .content li { margin-bottom: 0.5rem; }
 .info-box { background: #eef2ff; border-left: 4px solid #6366f1; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 .success-box { background: #f0fdf4; border-left: 4px solid #10b981; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 .warning-box { background: #fef3c7; border-left: 4px solid #f59e0b; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 table { width: 100%; border-collapse: collapse; margin: 1.5rem 0; font-size: 0.9rem; }
 th, td { padding: 0.75rem; text-align: left; border-bottom: 1px solid #e5e7eb; }
 th { background: #f8fafc; font-weight: 600; }
 .compare-card { background: white; border: 1px solid #e5e7eb; border-radius: 12px; padding: 1.25rem; margin: 1rem 0; }
 .compare-card h4 { color: var(--primary); margin-bottom: 0.5rem; font-size: 1.1rem; }
 .cta-box { background: linear-gradient(135deg, var(--primary), #2a7d83); color: white; padding: 2rem; border-radius: 16px; text-align: center; margin: 3rem 0; }
 .cta-btn { display: inline-block; background: white; color: var(--primary); padding: 0.75rem 1.5rem; border-radius: 8px; text-decoration: none; font-weight: 600; }
 
 @media (max-width: 640px) { h1 { font-size: 1.75rem; } article { padding: 6rem 1rem 3rem; } }
 </style>

    <meta property="og:title" content="GLP-1 mi, ESG mi? 9 Boyutta KapsamlÄ± KarÅŸÄ±laÅŸtÄ±rma">
    <meta property="og:description" content="Ä°laÃ§ tedavisi mi, endoskopik prosedÃ¼r mÃ¼? Etkinlik, kalÄ±cÄ±lÄ±k, maliyet ve daha fazlasÄ± â€” doÄŸru karar iÃ§in 9 kritik boyut.">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://uzunyasa.com/pages/blog/glp1-vs-esg-karsilastirma.html">
    <meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
    <meta property="og:site_name" content="UzunYaÅŸa">
    <meta property="og:locale" content="tr_TR">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="GLP-1 mi, ESG mi? 9 Boyutta KapsamlÄ± KarÅŸÄ±laÅŸtÄ±rma">
    <meta name="twitter:description" content="Ä°laÃ§ tedavisi mi, endoskopik prosedÃ¼r mÃ¼? Etkinlik, kalÄ±cÄ±lÄ±k, maliyet ve daha fazlasÄ± â€” doÄŸru karar iÃ§in 9 kritik boyut.">
    <link rel="canonical" href="https://uzunyasa.com/pages/blog/glp1-vs-esg-karsilastirma.html">
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "GLP-1 mi, ESG mi? 9 Boyutta KapsamlÄ± KarÅŸÄ±laÅŸtÄ±rma | UzunYaÅŸa",
  "description": "Ä°laÃ§ tedavisi mi, endoskopik prosedÃ¼r mÃ¼? Etkinlik, kalÄ±cÄ±lÄ±k, maliyet ve daha fazlasÄ± â€” doÄŸru karar iÃ§in 9 kritik boyut.",
  "author": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "url": "https://uzunyasa.com"
  },
  "publisher": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://uzunyasa.com/images/logo-icon-new.png"
    }
  },
  "datePublished": "2026-02-01",
  "dateModified": "2026-02-24",
  "mainEntityOfPage": "https://uzunyasa.com/pages/blog/glp1-vs-esg-karsilastirma.html",
  "image": "https://uzunyasa.com/images/og-default.png"
}
</script>
</head>
<body>
 <header class="header">
 <div class="header-inner">
 <a href="../../index.html"><img src="../../images/logo.svg" alt="UzunYaÅŸa" class="logo-img"></a>
 <a href="../blog.html" class="back-link">â† Blog</a>
 </div>
 </header>

 <article>
 <div class="post-meta-top">
 <span class="post-category"> KarÅŸÄ±laÅŸtÄ±rma</span>
 <span class="reading-time">â± 14 dk okuma â€¢ Åubat 2026</span>
 </div>
 
 <h1>GLP-1 mi, ESG mi? 9 Boyutta KapsamlÄ± KarÅŸÄ±laÅŸtÄ±rma</h1>
 <p class="subtitle">Ä°laÃ§ tedavisi mi, endoskopik prosedÃ¼r mÃ¼? Etkinlik, kalÄ±cÄ±lÄ±k, maliyet ve daha fazlasÄ± â€” doÄŸru karar iÃ§in bilmeniz gereken her ÅŸey.</p>

 <div class="featured-image"></div>

 <div class="content">
 <h2>HÄ±zlÄ± KarÅŸÄ±laÅŸtÄ±rma Tablosu</h2>
 <table>
 <tr><th>Boyut</th><th>GLP-1 Ä°laÃ§larÄ±</th><th>ESG</th></tr>
 <tr><td><strong>1. Etkinlik</strong></td><td>%15-22 kilo kaybÄ±</td><td>%18-20 kilo kaybÄ±</td></tr>
 <tr><td><strong>2. KalÄ±cÄ±lÄ±k</strong></td><td>DÃ¼ÅŸÃ¼k (bÄ±rakÄ±nca geri alÄ±m)</td><td>YÃ¼ksek (yapÄ±sal deÄŸiÅŸiklik)</td></tr>
 <tr><td><strong>3. Ä°nvazivlik</strong></td><td>Yok (enjeksiyon)</td><td>Minimal (endoskopik)</td></tr>
 <tr><td><strong>4. Ä°yileÅŸme</strong></td><td>Yok</td><td>3-7 gÃ¼n</td></tr>
 <tr><td><strong>5. Maliyet</strong></td><td>YÃ¼ksek (aylÄ±k devam)</td><td>Orta-yÃ¼ksek (tek seferlik)</td></tr>
 <tr><td><strong>6. Yan Etkiler</strong></td><td>GI semptomlar, kas kaybÄ±</td><td>Hafif, kÄ±sa sÃ¼reli</td></tr>
 <tr><td><strong>7. Ek Faydalar</strong></td><td>KardiyovaskÃ¼ler, bÃ¶brek</td><td>SÄ±nÄ±rlÄ±</td></tr>
 <tr><td><strong>8. Geri DÃ¶nÃ¼ÅŸÃ¼m</strong></td><td>Tam</td><td>KÄ±smen</td></tr>
 <tr><td><strong>9. Uygunluk</strong></td><td>BMI 27+</td><td>BMI 30-40</td></tr>
 </table>

 <h2>1. Etkinlik: Ne Kadar Kilo Verilir?</h2>
 <div class="compare-card">
 <h4> GLP-1 Ä°laÃ§larÄ±</h4>
 <ul>
 <li>Semaglutid 2.4 mg (Wegovy): <strong>~%15</strong> TBWL (68 hafta) ğŸŸ¢ (STEP 1, RCT, n=1961)</li>
 <li>Tirzepatid 15 mg (Zepbound): <strong>%22.5</strong> TBWL (72 hafta) ğŸŸ¢ (SURMOUNT-1, RCT, n=2539)</li>
 </ul>
 </div>
 <div class="compare-card">
 <h4> ESG</h4>
 <ul>
 <li>12 ayda: <strong>%18-20</strong> TBWL ğŸŸ¢ (MERIT, RCT, n=209)</li>
 <li>5 yÄ±lda: <strong>%15.9</strong> korunuyor ğŸŸ¡ (Sharaiha et al., tek merkezli kohort)</li>
 </ul>
 </div>
 <p><strong>DeÄŸerlendirme:</strong> Tirzepatid en yÃ¼ksek kilo kaybÄ±nÄ± saÄŸlamaktadÄ±r. ESG ve semaglutid benzer etkinlikte gÃ¶rÃ¼nmekle birlikte, ESG'nin yapÄ±sal etkisi daha kalÄ±cÄ± sonuÃ§lar sunabilmektedir.</p>

 <h2>2. KalÄ±cÄ±lÄ±k: BÄ±rakÄ±nca Ne Olur?</h2>
 <div class="warning-box">
 <strong> GLP-1 Ä°laÃ§larÄ±:</strong> BÄ±rakÄ±ldÄ±ÄŸÄ±nda 1 yÄ±l iÃ§inde kaybedilen kilonun <strong>%67'si</strong> geri alÄ±nmaktadÄ±r ğŸŸ¢ (STEP 1 uzatma Ã§alÄ±ÅŸmasÄ±, Wilding et al., JAMA 2022).
 </div>
 <div class="success-box">
 <strong> ESG:</strong> 5 yÄ±lda ortalama geri alÄ±m <strong>2.9 kg</strong>. YapÄ±sal deÄŸiÅŸiklik kalÄ±cÄ±lÄ±ÄŸÄ± desteklemektedir ğŸŸ¡ (Sharaiha et al., tek merkezli kohort, 2024).
 </div>

 <h2>3. Ä°nvazivlik ve Ä°yileÅŸme</h2>
 <table>
 <tr><th>Ã–zellik</th><th>GLP-1</th><th>ESG</th></tr>
 <tr><td>ProsedÃ¼r</td><td>HaftalÄ±k enjeksiyon</td><td>Tek seferlik endoskopi</td></tr>
 <tr><td>Anestezi</td><td>Yok</td><td>Genel/sedasyon</td></tr>
 <tr><td>Hastane yatÄ±ÅŸÄ±</td><td>Yok</td><td>0-1 gece</td></tr>
 <tr><td>Ä°ÅŸe dÃ¶nÃ¼ÅŸ</td><td>AynÄ± gÃ¼n</td><td>3-7 gÃ¼n</td></tr>
 </table>

 <h2>4. Yan Etkiler</h2>
 <h3>GLP-1 Ä°laÃ§larÄ±</h3>
 <ul>
 <li><strong>BulantÄ±:</strong> %30-45 ğŸŸ¢ (STEP Ã§alÄ±ÅŸmalarÄ±)</li>
 <li><strong>Kusma:</strong> %15-25</li>
 <li><strong>Kas kaybÄ±:</strong> Kaybedilen kilonun yaklaÅŸÄ±k %39'u yaÄŸsÄ±z kÃ¼tleden ğŸŸ¡ (STEP 1 DXA alt Ã§alÄ±ÅŸmasÄ±)</li>
 <li>GI yan etkiler Ã§oÄŸunlukla ilk haftalarda azalmaktadÄ±r</li>
 </ul>

 <h3>ESG</h3>
 <ul>
 <li><strong>BulantÄ±/kusma:</strong> Ä°lk 1-3 gÃ¼n, sonra geÃ§er</li>
 <li><strong>Ciddi komplikasyon:</strong> ~%1.5</li>
 <li><strong>Kas kaybÄ±:</strong> Minimal</li>
 </ul>

 <h2>5. Ek SaÄŸlÄ±k FaydalarÄ±</h2>
 <div class="info-box">
 <strong> GLP-1 Ek SaÄŸlÄ±k FaydalarÄ±:</strong>
 <ul>
 <li>MajÃ¶r kardiyovaskÃ¼ler olaylarÄ± (MACE) <strong>%20</strong> azaltmaktadÄ±r ğŸŸ¢ (SELECT, RCT, n=17.604, HR 0.80). Ancak tÃ¼m nedenlere baÄŸlÄ± mortalite azalmasÄ± istatistiksel olarak anlamlÄ± bulunmamÄ±ÅŸtÄ±r (HR 0.81, p=0.08).</li>
 <li>BÃ¶brek hastalÄ±ÄŸÄ± progresyonunu <strong>%24</strong> yavaÅŸlatmaktadÄ±r ğŸŸ¢ (FLOW, RCT, HR 0.76)</li>
 <li>KaraciÄŸer yaÄŸlanmasÄ±nda (MASLD) dÃ¼zelme bildirilmektedir ğŸŸ¡ (Faz 2 Ã§alÄ±ÅŸmalar; faz 3 verileri beklenmektedir)</li>
 </ul>
 </div>
 <p>ESG'nin kilo kaybÄ± dÄ±ÅŸÄ±nda bu tÃ¼r ek organ koruyucu etkiler gÃ¶sterdiÄŸine dair yeterli kanÄ±t henÃ¼z bulunmamaktadÄ±r.</p>

 <h2>6. Maliyet (5 YÄ±llÄ±k)</h2>
 <table>
 <tr><th></th><th>GLP-1 (Wegovy)</th><th>ESG</th></tr>
 <tr><td>5 yÄ±llÄ±k toplam</td><td><strong>~950.000 TL</strong></td><td><strong>~180.000 TL</strong></td></tr>
 </table>

 <h2>Karar Rehberi</h2>
 <h3>GLP-1 tercih edilebilir:</h3>
 <ul>
 <li>Herhangi bir prosedÃ¼r istemiyorsanÄ±z</li>
 <li>KardiyovaskÃ¼ler veya bÃ¶brek hastalÄ±ÄŸÄ±nÄ±z varsa</li>
 <li>BMI 27-30 arasÄ±ysa</li>
 <li>Maliyet engel deÄŸilse</li>
 </ul>

 <h3>ESG tercih edilebilir:</h3>
 <ul>
 <li>Uzun vadeli/Ã¶mÃ¼r boyu ilaÃ§ istemiyorsanÄ±z</li>
 <li>BMI 30-40 arasÄ±ysa</li>
 <li>Maliyet Ã¶nemliyse</li>
 <li>KalÄ±cÄ± Ã§Ã¶zÃ¼m arÄ±yorsanÄ±z</li>
 </ul>

 <h3>Kombinasyon?</h3>
 <p>BazÄ± hastalar iÃ§in <strong>ESG + dÃ¼ÅŸÃ¼k doz GLP-1</strong> kombinasyonu deÄŸerlendirilebilir â€” yapÄ±sal kÄ±sÄ±tlama ve metabolik destek birlikteliÄŸi. Bu yaklaÅŸÄ±ma dair kontrollÃ¼ Ã§alÄ±ÅŸma verileri henÃ¼z sÄ±nÄ±rlÄ±dÄ±r ğŸ”´ (vaka serileri ve pilot Ã§alÄ±ÅŸmalar).</p>

 <h4>ğŸ“š Kaynaklar</h4>
 <ol>
 <li>Abu Dayyeh BK, et al. "Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT)." <em>Lancet</em>, 2022; 400(10350):441-451. DOI: 10.1016/S0140-6736(22)01280-6</li>
 <li>Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." <em>New England Journal of Medicine</em>, 2021; 384(11):989-1002. DOI: 10.1056/NEJMoa2032183</li>
 <li>Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." <em>New England Journal of Medicine</em>, 2022; 387(3):205-216. DOI: 10.1056/NEJMoa2206038</li>
 <li>Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide." <em>Diabetes, Obesity and Metabolism</em>, 2022; 24(8):1553-1564. DOI: 10.1111/dom.14725</li>
 <li>Sharaiha RZ, et al. "Five-Year Outcomes of Endoscopic Sleeve Gastroplasty." <em>Clinical Gastroenterology and Hepatology</em>, 2024; 22(1):91-99. DOI: 10.1016/j.cgh.2023.05.013</li>
 <li>Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." <em>New England Journal of Medicine</em>, 2023; 389(24):2221-2232. DOI: 10.1056/NEJMoa2307563</li>
 </ol>

 
 



 



 <!-- BLOG SUMMARY - Auto-generated -->
 <div class="blog-summary" style="margin-top: 4rem; padding-top: 2rem; border-top: 2px solid #e5e7eb;">
 <div style="display: flex; align-items: center; gap: 12px; margin-bottom: 1.5rem;">
 <div style="width: 4px; height: 32px; background: linear-gradient(to bottom, #195157, #2a7d83); border-radius: 2px;"></div>
 <h2 style="margin: 0; font-family: 'Playfair Display', serif; font-size: 1.75rem; color: #195157;">Ã–zet</h2>
 </div>
 
 <blockquote style="margin: 0 0 1.5rem 0; padding: 1.5rem 2rem; background: linear-gradient(135deg, #f0fdf4 0%, #ecfeff 100%); border-left: 4px solid #195157; border-radius: 0 12px 12px 0; font-size: 1.1rem; line-height: 1.8; color: #374151; font-style: italic;">
 Ä°laÃ§ tedavisi mi, endoskopik prosedÃ¼r mÃ¼? Etkinlik, kalÄ±cÄ±lÄ±k, maliyet ve daha fazlasÄ± â€” doÄŸru karar iÃ§in 9 kritik boyut.
 </blockquote>
 
 <div style="margin-bottom: 1.5rem;">
 <p style="font-weight: 600; color: #195157; margin-bottom: 0.75rem; font-size: 0.95rem;"> Bu rehberde:</p>
 <ul style="list-style: none; padding: 0; margin: 0; display: grid; gap: 0.5rem;">
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> HÄ±zlÄ± KarÅŸÄ±laÅŸtÄ±rma Tablosu</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> 1. Etkinlik: Ne Kadar Kilo Verilir?</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> 2. KalÄ±cÄ±lÄ±k: BÄ±rakÄ±nca Ne Olur?</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> 3. Ä°nvazivlik ve Ä°yileÅŸme</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> 4. Yan Etkiler</li>
 </ul>
 </div>
 
 <!-- Visual Summary Slider (swipe on mobile) -->
 <div style="margin: 2rem 0; padding: 1.5rem; background: #f8fafc; border-radius: 16px;">
 <p style="font-weight: 600; color: #195157; margin-bottom: 1rem; font-size: 0.95rem;"> GÃ¶rsel Ã–zet:</p>
 <div style="display: flex; overflow-x: auto; scroll-snap-type: x mandatory; gap: 12px; border-radius: 12px; -webkit-overflow-scrolling: touch; scrollbar-width: none; -ms-overflow-style: none;">
 <style>.visual-slider::-webkit-scrollbar { display: none; }</style>
 <a href="../../images/social/glp1-vs-esg-karsilastirma-slide1.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-vs-esg-karsilastirma-slide1.jpg" alt="Kapak" style="width: 100%; display: block;">
 </a>
 <a href="../../images/social/glp1-vs-esg-karsilastirma-slide2.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-vs-esg-karsilastirma-slide2.jpg" alt="Ä°Ã§erik" style="width: 100%; display: block;">
 </a>
 <a href="../../images/social/glp1-vs-esg-karsilastirma-slide3.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-vs-esg-karsilastirma-slide3.jpg" alt="Ã–zet" style="width: 100%; display: block;">
 </a>
 <a href="../../images/social/glp1-vs-esg-karsilastirma-slide4.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-vs-esg-karsilastirma-slide4.jpg" alt="CTA" style="width: 100%; display: block;">
 </a>
 </div>
 <p style="text-align: center; margin-top: 0.75rem; font-size: 0.85rem; color: #6b7280;"> KaydÄ±rarak diÄŸerlerini gÃ¶rÃ¼n</p>
 </div>
 
 <div style="display: flex; flex-wrap: wrap; gap: 8px; padding-top: 1rem; border-top: 1px solid #e5e7eb;">
 <span style="font-size: 0.8rem; color: #9ca3af;">#uzunyasa</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#saÄŸlÄ±k</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#glp1</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#vs</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#esg</span>
 </div>
 </div>
 <!-- END BLOG SUMMARY -->


<div class="cta-box">
 <h3>Size uygun tedaviyi keÅŸfedin</h3>
 <p>KiÅŸiselleÅŸtirilmiÅŸ deÄŸerlendirme iÃ§in testimizi tamamlayÄ±n</p>
 <a href="../test.html" class="cta-btn">Teste BaÅŸla â†’</a>
 </div>
 </div>
 </article>

 <footer><p style="font-size:0.85rem;font-style:italic;opacity:0.7;margin-bottom:0.5rem;">TÃ¼rkiye uzun yaÅŸasÄ±n diye.</p><p>Â© 2026 UzunYaÅŸa. <a href="https://tyzd.org" target="_blank" style="color:inherit;text-decoration:underline;">TÄ±pta Yapay Zeka DerneÄŸi</a> giriÅŸimidir.</p></footer>
<script src="../../scripts/animations.js"></script>
</body>
</html>
